更新于：2024-11-01

Pulmonary Vascular Disease

肺血管疾病

更新于：2024-11-01

基本信息

别名

Pulmonary Vascular Disorder、Pulmonary vascular disorder、Pulmonary vascular disorder NOS

+ [6]

简介

A category of non-neoplastic disorders that affect the blood vessels in the lungs. Representative examples include pulmonary embolism, pulmonary hypertension, and arteriovenous malformations.

关联

项与肺血管疾病相关的药物

Macitentan

马昔腾坦

靶点

ETA x ETB

作用机制

ETA拮抗剂 [+1]

在研机构

Actelion Pharmaceuticals US, Inc. [+7]

原研机构

Actelion Pharmaceuticals Ltd.

在研适应症

结缔组织病 [+2]

非在研适应症

镰状细胞血症 [+11]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2013-10-18

Riociguat

利奥西呱

靶点

sGC

作用机制

sGC刺激剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2013-10-08

Anti-human T Lymphocyte Rabbit Immunoglobulin

抗人T细胞兔免疫球蛋白

靶点-

作用机制

免疫抑制剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

中国

首次获批日期2009-07-17

项与肺血管疾病相关的临床试验

NCT06331208 / RecruitingN/AIIT

Mechanisms of Pulmonary Vascular Dysfunction in Heart Failure

Heart failure (HF) patients often develop pulmonary hypertension (PH) that leads to transition into a biventricular HF with poor prognosis.
There are two PH components: 1) passive transmission of increased left atrial pressure, 2) heart failure (HF) related pulmonary vascular dysfunction (PVD) with increased vascular resistance. Intriguingly, only some, but not all HF patients develop heart failure-related PVD. The mechanisms and non-invasive detection of HF-PVD are poorly understood and are the focus of the current grant application. Development of PVD is linked to insufficiently characterized metabolic factors that may be mediators of HF-PVD.
Untargeted metabolomics is an emerging powerful platform for the discovery of pathways linked to diseases. Its specificity can be further enhanced using transpulmonary gradient sampling.
Part A of the project aims to identify novel metabolites associated with the presence of PVD in patients with HF that can serve as biomarkers or targets and will provide biologic insights into PVD. Part C will assess the effects of reverting of metabolic alterations (identified in part A) by a drug/diet on pulmonary vasculature in experimental HF-related PVD. The "gold standard" for the detection of PVD is right heart catheterization, which is invasive and risky. Heart failure-related PVD is therefore often diagnosed late.
There is a need for noninvasive tests that may help to detect PVD in early stages and can be done repeatedly. Recent advances in artificial intelligence (AI)-assisted automated quantitative analysis of lung texture from low-dose contrast-free high-resolution CT images allow to quantify lung water content, interstitial changes or vessel volume, and may provide clues for detection of heart failure-related PVD. Such an approach, not tested yet, will be utilized for the detection of HF-PVD (part B). Clinical and functional characteristics of lung circulation (exercise hemodynamics, diffusion capacity, perfusion) will be analyzed in relation to quantitative CT data.

开始日期2024-08-23

申办/合作机构

Institute of Clinical and Experimental Medicine

NCT06195059 / RecruitingN/AIIT

Assessment of Pulmonary Blood Volume Using Contrast Echocardiography During Exercise

The purpose of this study is to evaluate whether pulmonary blood volume (PBV) derived from contrast echocardiography can serve as a non-invasive surrogate for invasive pulmonary artery wedge pressure (PAWP) during exercise. Also, to compare changes in PBV with exercise in patients with and without heart failure and pulmonary vascular disease.

开始日期2024-07-30

申办/合作机构

Mayo Clinic

NCT06480656 / RecruitingN/AIIT

Eccentric Cycling Exercise During Pulmonary Rehabilitation in Pulmonary Vascular Disease

Eccentric cycling allows high intensities with low metabolic costs. Therefore the aim of this project is to investigate whether ECC improves exercise capacity and possibly hemodynamics during prolonged rehabilitation programs in patients with PVD

开始日期2024-05-29

申办/合作机构

University of Zurich

100 项与肺血管疾病相关的临床结果

登录后查看更多信息

100 项与肺血管疾病相关的转化医学

登录后查看更多信息

0 项与肺血管疾病相关的专利（医药）

登录后查看更多信息

4,448

项与肺血管疾病相关的文献（医药）

2024-12-31·COPD: Journal of Chronic Obstructive Pulmonary Disease

Alleviatory Role of Panax Notoginseng Saponins in Modulating Inflammation and Pulmonary Vascular Remodeling in Chronic Obstructive Pulmonary Disease: mechanisms and Implications

Article

作者: Zhang, Xiaomei ; Hu, Yanan ; Han, Niping ; Xu, Ou ; Fan, Qiuyang ; Lv, Bijun ; Qiao, Bo

COPD is an inflammatory lung disease that limits airflow and remodels the pulmonary vascular system. This study delves into the therapeutic potential and mechanistic underpinnings of Panax notoginseng Saponins (PNS) in alleviating inflammation and pulmonary vascular remodeling in a COPD rat model. Symmap and ETCM databases provided Panax notoginseng-related target genes, and the CTD and DisGeNET databases provided COPD-related genes. Intersection genes were subjected to protein-protein interaction analysis and pathway enrichment to identify downstream pathways. A COPD rat model was established, with groups receiving varying doses of PNS and a Roxithromycin control. The pathological changes in lung tissue and vasculature were examined using histological staining, while molecular alterations were explored through ELISA, RT-PCR, and Western blot. Network pharmacology research suggested PNS may affect the TLR4/NF-κB pathway linked to COPD development. The study revealed that, in contrast to the control group, the COPD model exhibited a significant increase in inflammatory markers and pathway components such as TLR4, NF-κB, HIF-1α, VEGF, ICAM-1, SELE mRNA, and serum TNF-α, IL-8, and IL-1β. Treatment with PNS notably decreased these markers and mitigated inflammation around the bronchi and vessels. Taken together, the study underscores the potential of PNS in reducing lung inflammation and vascular remodeling in COPD rats, primarily via modulation of the TLR4/NF-κB/HIF-1α/VEGF pathway. This research offers valuable insights for developing new therapeutic strategies for managing and preventing COPD.

2024-12-01·European Journal of Medicinal Chemistry

Allosteric site identification, virtual screening and discovery of a sulfonamide Hsp110-STAT3 interaction inhibitor for the treatment of hypoxic pulmonary arterial hypertension

Article

作者: Hu, Liqing ; Gao, Ruizhe ; Zhao, Congke ; Hu, Yuanbo ; Tan, Wenhua ; Wu, Yan ; Wang, Yu ; Li, Qianbin ; Li, Mengqi

Pulmonary arterial hypertension (PAH) is a severe pulmonary vascular disorder marked by vascular remodeling, which is linked to the malignant phenotypes of pulmonary vascular cells. The prevailing therapeutic approaches for PAH tend to neglect the potential role of vascular remodeling, leading to the clinical prognosis remains poor. Previously, we first demonstrated that heat shock protein (Hsp110) was significantly activated to boost Hsp110-STAT3 interaction, which resulted in abnormal proliferation and migration of human pulmonary arterial endothelial cells (HPAECs) under hypoxia. In the present study, we initially postulated the allosteric site of Hsp110, performed a virtual screening and biological evaluation studies to discover novel Hsp110-STAT3 interaction inhibitors. Here, we identified compound 29 (AN-329/43448068) as the effective inhibitor of HPAECs proliferation and the Hsp110-STAT3 association with good druggability. In vitro, 29 significantly impeded the chaperone function of Hsp110 and the malignant phenotypes of HPAECs. In vivo, 29 remarkably attenuated pulmonary vascular remodeling and right ventricular hypertrophy in hypoxia-induced PAH rats (i.g). Altogether, our data support the conclusion that it not only provides a novel lead compound but also presents a promising approach for subsequent inhibitor development targeting Hsp110-STAT3 interaction.

2024-12-01·Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease

Sec13 promotes glycolysis by inhibiting Ubqln1 mediated Pgm1 ubiquitination in ALI

Article

作者: Li, Fang ; Liu, Shuai ; Wu, Dongdong ; Zhang, Zhao ; Wang, Jiannan ; Wu, Qiuge ; Zhang, Hui ; Wang, Yang

Acute lung injury (ALI) is a severe lung damage characterized by acute hypoxemia, increased pulmonary vascular permeability, and inflammatory reactions. Despite current treatments, mortality from ALI remains high. This study found that Sec13 is highly expressed in ALI and regulates it by glycolysis and epithelial-mesenchymal transition (EMT). In an ALI mouse model and cell model, Sec13 expression increased, accompanied by enhanced glycolysis, EMT, and inflammation. Sec13 knockdown suppressed these effects, alleviating ALI. Sec13 forms a protein complex with Pgm1, an enzyme regulating glucose-6-phosphate (G6P) production, and Ubqln1, an ubiquitin ligase. Sec13 inhibits Ubqln1-mediated Pgm1 ubiquitination, thereby stabilizing Pgm1. In ALI, Pgm1 binding to Sec13 increased but binding to Ubqln1 decreased. Sec13 knockdown decreased lactate, G6P, EMT markers, and inflammatory cytokines. Pgm1 knockdown produced similar effects. Ubqln1 overexpression suppressed inflammation but decreased Pgm1 expression. In conclusion, Sec13 plays a key role in ALI by inhibiting Ubqln1-mediated Pgm1 ubiquitination, affecting glycolysis and EMT. Sec13 and Pgm1 may be new targets for treating ALI.

项与肺血管疾病相关的新闻（医药）

2024-10-25

·PRNewswire

Corvia Medical Announces Three-Year Clinical Trial Results Confirming Significant and Durable Benefits of the Corvia Atrial Shunt in Heart Failure Patients

44% reduction in total heart failure event rate and ongoing improvements in quality of life in responder group patients implanted with shunt TEWKSBURY, Mass., Oct. 25, 2024 /PRNewswire/ -- Corvia Medical, Inc, a company dedicated to transforming the treatment of heart failure, today announced impressive three-year results from its REDUCE LAP-HF II randomized clinical trial confirming safety and sustained efficacy of the Corvia® Atrial Shunt in selected heart failure patients with preserved (HFpEF) or mildly reduced (HFmrEF) ejection fraction. The results were published in The American Heart Journal. REDUCE LAP-HF II is the world's first phase III trial to evaluate safety and efficacy of an atrial shunt in heart failure patients. The study of 626 patients previously identified a responder group representing half of all study participants. This group consisted of patients without latent pulmonary vascular disease or a cardiac rhythm management device. At three years, the 161 responder patients receiving the Corvia Atrial Shunt experienced 44% fewer combined inpatient and outpatient heart failure events compared to the control group of 152 patients. The shunt group also reported a clinically meaningful 2.5 times greater improvement in Kansas City Cardiomyopathy Questionnaire (KCCQ) overall summary score, indicating improved quality of life with less fatigue, reduced shortness of breath, and fewer activity restrictions. No significant safety concerns have been identified with the Corvia Atrial Shunt. "What we've learned from this three-year data set is that the Corvia shunt results are not only strongly positive but demonstrably durable," said Sheldon Litwin, MD, Alicia Spaulding-Paolozzi Professor of Cardiology at Medical University of South Carolina and a lead researcher in the trial. "The absolute risk reduction for total heart failure events actually improves year by year over the two-year and one-year statistics. And with a majority of patients emphasizing quality of life even over reduced hospitalizations, the importance of the sharply improved KCCQ scores is magnified." "We are confident that the strong three-year results will generate continued enthusiasm for atrial shunting among referring physicians, positioning it as a promising treatment option for eligible HFpEF patients," said Jan Komtebedde, Chief Medical Officer at Corvia Medical. "We are actively driving toward completion of RESPONDER-HF, a randomized, sham-controlled, confirmatory trial conducted at up to 80 centers worldwide," added George Fazio, Chief Executive Officer at Corvia Medical, "which we expect to generate the final data set needed for FDA approval of the Corvia Atrial Shunt." About heart failure (HF) and the Corvia Atrial Shunt More than 26 million people worldwide have HF, and the majority have HFpEF, making it the largest unmet clinical need in cardiovascular medicine. The Corvia Atrial Shunt is designed to reduce elevated left atrial pressure (LAP), the primary contributor to HF symptoms in HFpEF patients, by creating a passage between the left and right atria, reducing HF events and improving quality of life. About Corvia Medical, Inc. Corvia Medical, Inc. is revolutionizing the treatment of heart failure through novel transcatheter cardiovascular devices. Founded in 2009 and headquartered in Tewksbury, MA, Corvia is dedicated to transforming the standard of care for heart failure treatment, enabling patients to reclaim their lives. The Corvia Atrial Shunt was granted Breakthrough Device designation by the FDA in 2019. Privately held, the company is backed by Third Rock Ventures, General Catalyst Partners, AccelMed, Lumira Ventures, Edwards Lifesciences, and an undisclosed strategic investor. Visit . For information regarding RESPONDER-HF study eligibility, please visit . MEDIA CONTACT: Lisa Ensz +1 978-654-6120 [email protected] SOURCE Corvia Medical, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

临床3期临床结果AHA会议突破性疗法

2024-08-05

·李氏大药厂

精彩会议回顾 | 中欧病例魔方心内科专题第二期：慢性血栓栓塞性及结缔组织病相关性肺动脉高压

7月24日，由意大利帕多瓦大学联合李氏大药厂控股有限公司（简称“李氏大药厂”或“集团”，股份编号：00950）共同发起的跨国教育项目——中欧病例魔方心内科专题第二期：“慢性血栓栓塞性及结缔组织病相关性肺动脉高压”在线上成功举办。本期会议特邀首都医科大学附属北京朝阳医院呼吸与危重症医学科杨媛华教授担任中方主席，意大利帕多瓦大学Luca Spiezia教授担任欧方主席。首都医科大学附属北京朝阳医院呼吸与危重症医学科龚娟妮教授、帕多瓦大学帕多瓦医院血栓和出血性疾病专科Marco Zacchia博士担任会议讲者，首都医科大学附属北京朝阳医院呼吸与危重症医学科李积凤教授担任讨论嘉宾，各位专家共同就慢性血栓栓塞性肺动脉高压以及结缔组织病相关性肺动脉高压的疾病诊断及治疗等问题进行交流和探讨。会议主席致辞会议伊始，中方主席杨媛华教授致开场词，表示很高兴能有这样的机会与欧洲学者就结缔组织病相关性及慢性血栓栓塞性肺动脉高压病例进行讨论、交流。杨教授表示，中国结缔组织病患者中，系统性红斑狼疮患者较多，诊断通常较晚，所以有很多红斑狼疮合并肺动脉高压的患者。在国外，结缔组织病的疾病谱和我们有很大的区别，杨教授非常期待通过这样的交流机会，能与欧洲的先进中心交流、分享该类患者的诊断与治疗。欧方Luca Spiezia教授表示，很高兴同中方专家进行经验分享和交流。意大利有非常多肺动脉高压患者，今天分享的是一例慢性血栓栓塞性肺动脉高压患者的诊疗。希望今天的中欧会议能让双方从不同的角度学习到更多关于肺血管疾病的知识。学术交流 01 首都医科大学附属北京朝阳医院呼吸与危重症医学科龚娟妮教授：治疗“双达标”，CTD-PAH患者诊治一例龚娟妮教授首先进行了分享。这是一例年轻女性患者，因“活动后气短伴咳嗽咳痰2月余”入院，在体格检查时，就注意到该患者颜面部皮肤较常人“偏红”，且心率增快（108次/分），P2＞A2。心脏超声提示患者的右房、右室扩大，三尖瓣反流速度419cm/s，TAPSE/SPAP 12.6/74.6:0.17mm/mmHg。进一步通过V/Q扫描、肺功能检查等排除CTEPH、呼吸系统疾病相关性PH后，进行了右心导管及抗体检查，确诊了结缔组织相关性肺动脉高压。明确诊断及病因后，朝阳医院肺动脉高压团队基于目前指南推荐的“双达标”疗法，对该患者的原发疾病进行系统性治疗的同时对肺动脉高压进行基于危险分层的靶向药治疗。在后续的随访中，运用最新的四分法无创评估，患者目前症状明显改善、活动耐力恢复正常、血流动力学参数良好。 02 帕多瓦大学帕多瓦医院血栓和出血性疾病专科Marco Zacchia博士：血栓栓塞继发肺动脉高压的治疗Marco Zacchia博士分享了一例继发于胆囊切除术后深静脉血栓和肺栓塞的慢性血栓栓塞性肺动脉高压病例。该患者为36岁中年男性，有反复的肺栓塞病史，在接受抗凝溶栓治疗六个月后，呼吸困难等症状仅略有改善，进行肺部CT血管造影显示，患者仍有外周肺栓塞，且V/Q扫描提示多个血流减少区域，考虑慢性肺栓塞。最终，在排除了其他可能疾病后，确诊为继发于未治愈的静脉血栓栓塞症的慢性血栓栓塞性肺动脉高压，并选用靶向药进行治疗。病例分享后，Marco Zacchia博士还就CTEPH的发病机理、诊断及鉴别诊断、处理原则等进行了分享。讨论环节讨论环节，两位主席以及首都医科大学附属北京朝阳医院的李积凤教授进行了充分的交流。针对结缔组织病相关性肺动脉高压，明确诊断后的“双达标”治疗尤为关键。我们不仅需要关注原发病中结缔组织病活动度的控制，还需要基于肺动脉高压危险分层，对患者进行肺动脉高压靶向药的充分治疗。李积凤教授强调，对于一些中高危患者，应该考虑使用静脉或皮下前列环素进行治疗。针对慢性血栓栓塞性肺动脉高压，中方教授提出，我们常见的CTEPH患者大多是由于栓塞性疾病发现不及时、错过了最佳的抗凝溶栓治疗窗，但今天分享的患者诊断非常及时、准确，依然发展成了慢性血栓并导致了肺动脉高压，Luca Spiezia教授表示，这可能与炎性机制的介导相关，这提示我们，应该重视炎性机制在血栓形成及发展过程中的病理作用，并重视患者的个性化治疗。会议主席总结致词最后，双方主席教授作总结发言，感谢中欧双方精彩的病例分享，感谢双方教授的参与，期待下期的中欧会议的举办。参考文献： [1]国家心血管病中心肺动脉高压专科联盟国家,心血管病专家委员会右心与肺血管病专业委员会. 中国肺动脉高压诊治临床路径[J]. 中国循环杂志,2023,38(7):691-703. DOI:10.3969/j.issn.1000-3614.2023.07.002. [2] 中华医学会呼吸病学分会肺栓塞与肺血管病学组,中国医师协会呼吸医师分会肺栓塞与肺血管病工作委员会,全国肺栓塞与肺血管病防治协作组,等. 中国肺动脉高压诊断与治疗指南（2021版）[J]. 中华医学杂志,2021,101(1):11-51. DOI:10.3760/cma.j.cn112137-20201008-02778. [3]Jenny, Yang., Michael M, Madani., Ehtisham, Mahmud., Nick H, Kim.(2023). Evaluation and Management of Chronic Thromboembolic Pulmonary Hypertension. Chest, 164(2), 0. doi:10.1016/j.chest.2023.03.029. [4]Jiuliang, Zhao,Qian, Wang,Xiaoyue, Deng et al. The treatment strategy of connective tissue disease associated pulmonary arterial hypertension: Evolving into the future.[J] .Pharmacol Ther, 2022, 239: 0. 下滑查看更多会议视频回顾扫描二维码查看本文仅供专业人士一起探讨最有价值医学知识及相关科普，非广告用途撰稿：何杨柯排版：黄文浩校稿：何杨柯、王烨馨免责声明：本公众号发布或转载企业宣传资讯，仅供读者参考之用，并不构成收购、购买或认购依据，并不构成任何个人化的投资劝诱或建议。因本公布全部或任何部分内容而产生或因倚赖该等内容而引致的任何损失不承担任何责任。企业文化公共关系部出品与“李”同行招商热线 020-39062882

2024-07-29

·李氏大药厂

精彩会议回顾 | 2024年中欧医学继续教育项目——心内科第三期：肺血管狭窄相关疾病治疗现况

6月27日，由意大利帕多瓦大学联合李氏大药厂控股有限公司（简称“李氏大药厂”或“集团”，股份编号：00950）共同发起的跨国教育项目——“中欧医学继续教育项目心内科第三期：肺血管狭窄相关疾病治疗现况“在线成功举办。本期会议特邀四川省人民医院曹云山教授担任中方主席，意大利帕多瓦大学Castaldi Biagio教授担任欧方主席。四川省人民医院张云鹤博士、罗马圣卡米勒斯国际健康与医学科学大学的Francesco Prati博士担任会议讲者，广东省人民医院蒋鑫教授、四川省人民医院王文艳教授担任讨论嘉宾，各位专家共同就肺血管狭窄相关疾病的病因、临床处理等问题进行交流和探讨。会议主席致辞会议伊始，中方主席曹云山教授致开场词，表示很高兴能有这样的机会与欧洲学者就肺血管狭窄相关疾病以及肺动脉高压病例进行讨论、交流。曹教授表示，不同国家的疾病谱、发病率甚至疾病表现可能不同，开展更多这样的跨国交流有助于中欧间同道互相学习，汲取经验，最终惠及两地的患者。欧方Castaldi Biagio教授表示，很高兴同中方专家进行经验分享和交流。意大利有非常多肺动脉高压患者，今天分享的是两例儿童肺血管狭窄病变的病例。希望今天的中欧会议能让双方从不同的角度学习到更多关于肺血管疾病的知识。学术交流 01 罗马圣卡米勒斯国际健康与医学科学大学的Francesco Prati博士：帕多瓦儿科心脏病学导管室的典型病例分享Francesco Prati博士首先进行了分享。第一份病例是一例法洛四联症伴肺动脉闭锁+静脉体肺侧支循环的儿童。患儿2020年8月出生，确诊后2021年1月至今进行了多次心内介入手术，包括“主动脉至肺动脉侧支血管成形术”“主动脉至肺动脉侧支支架植入术”“左右肺动脉切割球囊”，Francesco Prati博士就每次手术的过程都进行了造影演示。第二份病例是一位更小的患儿，2022年出生后诊断为威廉姆斯综合征（Williams Syndrome），确诊后行主动脉成形术、外科成形术和扩大术，同时在内科介入室行“植入支架的双侧肺血管成形术”。 02 四川省人民医院张云鹤博士：肺血管狭窄的原因张云鹤博士分享了一例纤维性纵隔炎合并肺动脉高压的优质病例。曹教授团队对该患者选择了多次球囊血管成形术、支架植入术。病例分享后，张博士还就纤维性纵隔炎的发病机理、诊断及鉴别诊断、处理原则等进行了分享。讨论环节讨论环节，两位主席以及广东省人民医院蒋鑫教授、四川省人民医院王文艳教授进行了充分的交流。双方教授均认为，肺血管狭窄的病因复杂多变，临床医生需要熟练掌握肺动静脉、心血管系统的解剖结构才能真正理解和解释疾病的成因和转归。欧方教授提出，在该类疾病中，特别是面对有血管瘢痕狭窄的患者时，选择高压球囊治疗是较为理想的术式，在治疗有血管增生潜在病变的病灶时，切割球囊被认为是避免产生动脉瘤和血管断裂的好方法。中方教授表示同意，并与欧方教授就儿童威廉姆斯综合征患儿术后的长期预后进行了沟通和讨论。同时，曹云山教授就肺血管狭窄性疾病合并肺动脉高压患者是否能使用靶向药治疗这个问题指出，该类患者通常不是单纯的肺动脉病变，往往还伴有肺静脉系统的病变，在实际临床中会发现，部分患者可能症状会减轻，但部分患者疾病甚至会加重，所以需要非常谨慎。会议主席总结致词最后，会议主席曹云山教授做总结发言，感谢中欧双方精彩的病例分享，感谢双方教授的参与，期待下期的中欧会议的举办。参考文献： [1]E. Rodríguez, Soler R , Pombo F ,et al.Fibrosing mediastinitis: CT and MR findings[J]. 1998, 53(12):0-910.DOI:10.1016/s0009-9260(98)80218-3. [2]Khalid M , Khan I , Rahman Z ,et al.Fibrosing Mediastinitis: Uncommon Life-threatening Complication of Histoplasmosis[J].Cureus, 2018. DOI: 10.7759/cureus.2532. [3]Milesh,Patel,Frederic,et al.Fibrosing mediastinitis: a rare complication of histoplasmosis[J]. BMJ Case Reports, 2015. DOI: 10.1136/bcr-2015-212774. [4]Liao JP.Clinical characteristics and prognosis of mediastinal fibrosis[J].China Medical Abstracts (Internal Medicine), 2017 (02): 199-204. DOI: CNKI:SUN:ZYNE.0.2017-02-079. [5]曹云山,段一超,苏红玲.纤维纵隔炎致肺血管狭窄的诊治进展[J].中华心血管病杂志, 2020, 48(10):8.DOI:10.3760/cma.j.cn112148-20200214-00081. 下滑查看更多会议视频回顾扫描二维码查看本文仅供专业人士一起探讨最有价值医学知识及相关科普，非广告用途撰稿：何杨柯排版：黄文浩校稿：何杨柯、王烨馨免责声明：本公众号发布或转载企业宣传资讯，仅供读者参考之用，并不构成收购、购买或认购依据，并不构成任何个人化的投资劝诱或建议。因本公布全部或任何部分内容而产生或因倚赖该等内容而引致的任何损失不承担任何责任。与“李”同行招商热线 020-39062882